This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Newsletter Archive
EAU 2025
Go
Reset
Send Date
Subject
Created Date
ID
Asc
Desc
Bladder Cancer Controversies: Rapid-Fire Debates from EAU26
Sent on 01 April 2026
Targeting DNA Repair Pathways in Prostate Cancer EAU 2026
Sent on 16 March 2026
Data Shaping Care in Renal and Upper Tract Cancers from EAU 2026
Sent on 16 March 2026
EAU 2026 PSMA-Guided Therapy and New Intensification Strategies in Prostate Cancer
Sent on 15 March 2026
EAU 2026 Where Bladder Cancer Treatment Is Heading Next
Sent on 15 March 2026
EAU 2026: Surgery and Intravesical Therapy in NMIBC
Sent on 14 March 2026
EAU 2026: Bladder Sparing Treatment in Non-Muscle Invasive Bladder Cancer
Sent on 14 March 2026
EAU 2026 Evidence Shaping Prostate Cancer Screening, Imaging and Treatment
Sent on 13 March 2026
2026 European Association of Urology (EAU) Annual Meeting: Management of Oligometastatic Prostate Cancer: Not as Easy as It Seems
Sent on 13 March 2026
SUO 2025 Bladder-Sparing Innovation in High-Risk NMIBC
Sent on 06 December 2025
ESMO 2025: SunRISe-4 Results and Highlights Across MIBC and mUC
Sent on 21 October 2025
ESMO 2025: Trial Results from ENZARAD - PRESTO - EMBARK - CAPItello-281 - PSMAAddition
Sent on 21 October 2025
Advances in Imaging Based Theranostics from ESMO 2025
Sent on 19 October 2025
ESMO 2025: Renal Cell Carcinoma Focused on New Data Supporting Evolving Treatment Strategies
Sent on 19 October 2025
ESMO 2025: Enfortumab Vedotin + Pembrolizumab Drives Survival Gains in MIBC
Sent on 19 October 2025
ESMO 2025: Radioligand and Combination Strategies in Prostate Cancer
Sent on 18 October 2025
ESMO 2025 Trials Shaping What’s Next in Renal & Urothelial Cancer
Sent on 18 October 2025
ESMO 2025: Advancing Care in Metastatic Prostate Cancer and Beyond
Sent on 18 October 2025
European Society for Medical Oncology (ESMO) 2025: Defining New Standards in Urothelial Cancer Care
Sent on 17 October 2025
Emerging Strategies for NMIBC: EAU 2025 Bladder Cancer
Sent on 26 March 2025
EAU 2025 - Navigating Prostate Cancer: Clinical Decisions from Diagnosis to Disease Progression
Sent on 25 March 2025
Advancing Care in Bladder & UTUC: Takeaways from EAU 2025
Sent on 24 March 2025
Emerging Evidence in Advanced Prostate Cancer Care from the European Association of Urology (EAU) 2025
Sent on 23 March 2025
European Association of Urology (EAU) 2025: Biomarkers & Organ Sparing: Evolving Paradigms in Uro-Oncology
Sent on 23 March 2025
European Association of Urology (EAU) 2025 Hormone-Sensitive Prostate Cancer Management and Evolving Peri-Operative Strategies
Sent on 22 March 2025
European Association of Urology (EAU) 2025 What’s Shaping Bladder Cancer Care: Debates, Data & the Future
Sent on 21 March 2025
Coverage of the 2025 European Association of Urology (EAU) Congress Starts Friday
Sent on 19 March 2025
Display #
5
10
15
20
25
30
50
100
Results 1 - 27 out of 27
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free